1050 related articles for article (PubMed ID: 17498002)
1. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
[TBL] [Abstract][Full Text] [Related]
4. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
5. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
8. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
9. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
[TBL] [Abstract][Full Text] [Related]
11. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
[TBL] [Abstract][Full Text] [Related]
12. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
13. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
14. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
15. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Yuan F; Chen X; Wang C; Zhou A; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
[TBL] [Abstract][Full Text] [Related]
16. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
[TBL] [Abstract][Full Text] [Related]
17. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
Peng SJ; Yang CS; Ferng SH; Chen LY
Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
[TBL] [Abstract][Full Text] [Related]
18. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
[TBL] [Abstract][Full Text] [Related]
19. Effects of vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels.
Nakashima A; Yorioka N; Doi S; Masaki T; Ito T; Harada S
Bone; 2004 Mar; 34(3):579-83. PubMed ID: 15003806
[TBL] [Abstract][Full Text] [Related]
20. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
